Treatment of cancers of lymphocytic cells with product R

Abstract

A method of treating a patient suffering from cancers of lymph cells such as acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma comprises parenterally administering to said patient an effective acute lymphocytic leukemia treatment amount of Product R in a pharmaceutically acceptable formulation.

I claim:  
     
         1 . A method of treating a patient suffering from acute lymphocytic leukemia, comprising parenterally administering to said patient an effective acute lymphocytic leukemia treatment amount of Product R in a pharmaceutically acceptable formulation.  
     
     
         2 . The method of  claim 1 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.  
     
     
         3 . The method of  claim 1 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.  
     
     
         4 . A method of treating a patient suffering from chronic lymphocytic leukemia, comprising parenterally administering to said patient an effective chronic lymphocytic leukemia treatment amount of Product R in a pharmaceutically acceptable formulation.  
     
     
         5 . The method of  claim 4 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.  
     
     
         6 . The method of  claim 4 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.  
     
     
         7 . A method of treating a patient suffering from Hodgkin's disease, comprising parenterally administering to said patient an effective Hodgkin's disease treatment amount of Product R in a pharmaceutically acceptable formulation.  
     
     
         8 . The method of  claim 7 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.  
     
     
         9 . The method of  claim 7 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day. The treatment of patients with Hodgkin's disease with Product R.  
     
     
         10 . A method of treating a patient suffering from non-Hodgkin's lymphoma, comprising parenterally administering to said patient an effective non-Hodgkin's lymphoma treatment amount of Product R in a pharmaceutically acceptable formulation.  
     
     
         11 . The method of  claim 10 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.  
     
     
         12 . The method of  claim 10 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.  
     
     
         13 . A method of shrinking enlarged lymph nodes in patients with Hodgkin's disease or Non-Hodgkin's lymphoma, comprising parenterally administering to said patient an effective amount of Product R for shrinking lymph node in a pharmaceutically acceptable formulation.  
     
     
         14 . The method of  claim 13 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.  
     
     
         15 . The method of  claim 13 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.  
     
     
         16 . A method of shrinking enlarged spleen in patients with Hodgkin's disease or Non-Hodgkin's lymphoma, comprising parenterally administering to said patient an effective amount of Product R for shrinking spleen in a pharmaceutically acceptable formulation.  
     
     
         17 . The method of  claim 16 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.  
     
     
         18 . The method of  claim 16 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.  
     
     
         19 . A method of treating body wasting, lose of appetite and fatigue in patients suffering from acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, comprising parenterally administering to said patient an effective acute lymphocytic leukemia treatment amount of Product R in a pharmaceutically acceptable formulation.  
     
     
         20 . The method of  claim 19 , wherein said Product R is administered in a range from about 2.5 microliters to about 40 microliters per kilogram of body weight per day in a pharmaceutically acceptable formulation.  
     
     
         21 . The method of  claim 19 , wherein said Product R is administered in an amount of 2 ml per day for about 2-4 weeks and subsequently 1 ml per day.  
     
     
         22 . A method of treating a patient suffering from cancers of lymphocytic cells which comprises acute lymphocytic leukemia, chronic lymphocytic leukemia, Hodgkin's disease and non-Hodgkin's lymphoma, comprising parenterally administering to said patient an effective cancers of lymphocytic cells treatment amount of Product R in a pharmaceutically acceptable formulation.